SLC5A2 and gout: We observed a significant 0.85-fold (95% CI, 0.74-0.97; P = .02) risk for gout in patients receiving SGLT2 inhibitors compared with DPP4 inhibitors (Table), especially for those receiving empagliflozin (HR, 0.83; 95% CI, 0.69-0.98; P = .03).